Key result
Impaired kidney function, present in 28% of patients in the US REVEAL registry, and declines in eGFR of ≥10% were independently associated with increased mortality in pulmonary arterial hypertension.
Highlights the significant prognostic impact of coexisting chronic kidney disease and declining renal function on mortality in patients with pulmonary arterial hypertension.
Extract Pulmonary hypertension (PH) and chronic kidney disease frequently coexist, with each condition associated with increased mortality in the other [1]. In patients with pulmonary arterial hypertension (PAH), reduced estimated glomerular filtration rate (eGFR) is present in a considerable portion of patients. Data from 2368 patients enrolled in the US Registry to Evaluate Early and Long-term PAH Disease Management (REVEAL) showed that 28% had impaired kidney function, defined as an eGFR <60 mL·min⁻¹ per 1.73 m² at enrolment [2]. In this registry, impaired renal function was independently associated with increased mortality [2]. Both the absolute eGFR value and a decline in eGFR of ≥10% from baseline over a period of at least 1 year were linked to higher risk of death [3]. Similarly, in a separate cohort of 500 patients with PAH, even modest elevations in serum creatinine, starting as low as levels just above 1.0 mg·dL⁻¹, were associated with increased all-cause mortality [4].
No takes yet. Share an insight, caveat, or question.
Harbaum et al. (2025) conducted an editorial in Pulmonary arterial hypertension. Impaired kidney function was evaluated on Mortality. Impaired kidney function, present in 28% of patients in the US REVEAL registry, and declines in eGFR of ≥10% were independently associated with increased mortality in pulmonary arterial hypertension.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: